NCE-1 Intelligence & Market Opportunity

Empaveli

Pegcetacoplan

Immunomodulators

Subcutaneous Solution

Approval Date

14-May-21

NCE-1 Date

14-May-25

NCE Date

14-May-26

Commercial snapshot

Market performance & projections

Revenue ($M)

239

CAGR (%)

0.4146

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

298

2027

588

2028

776

2029

957

2030

1125

2031

1278

2032

1389

Molecule profile

Details & specifications

Molecule

Pegcetacoplan

Innovator

APELLIS PHARMACEUTICALS, INC.

Dosage Form

Subcutaneous Solution

Strength

1080 mg/20 mL (54 mg/mL)

Therapeutic Category

Immunomodulators

Usage

To treat paroxysmal nocturnal hemoglobinuria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.